Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPC3 CAR-T cells in hepatocellular carcinoma
NCT05344664Phase 1Unknown
- Sponsor
- Peking University
- Start
- Apr 2022
- Primary completion
- Oct 2024
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label trial of GPC3-CART cells in hepatocellular carcinoma (HCC), sponsored by Peking University. Primary endpoint: Percentage of adverse events at 3 months. Status: unknown.
02
Drugs
GPC3-CART cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05344664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05344664.